{"id":"sentagliptin-phosphate-single-dose","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DPP-4 inhibitors like sentagliptin phosphate work by blocking the enzyme DPP-4, which breaks down incretin hormones. This leads to increased levels of incretin hormones, which in turn stimulate the release of insulin from the pancreas in a glucose-dependent manner.","oneSentence":"Sentagliptin phosphate is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones to enhance glucose-dependent insulin secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:01.209Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07241897","phase":"PHASE3","title":"DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-12-15","conditions":"Ischemic Stroke, Diabete Mellitus","enrollment":312}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1255,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sentagliptin Phosphate - single dose","genericName":"Sentagliptin Phosphate - single dose","companyName":"Second Affiliated Hospital of Soochow University","companyId":"second-affiliated-hospital-of-soochow-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sentagliptin Phosphate is a small molecule with unknown mechanism of action, as its specific action is not described in the provided information. It has been studied in clinical trials as a single dose intervention for conditions including Ischemic Stroke and Diabetes Mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}